Clinical Trials Logo

Hepatitis C clinical trials

View clinical trials related to Hepatitis C.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT02935478 Suspended - Obesity Clinical Trials

Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation

Start date: October 18, 2017
Phase: N/A
Study type: Interventional

Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor and has a grave prognosis. Obesity is an epidemic in the US.Patients with HCC and obesity are not candidates for liver transplantation, depriving them of the best option for cure from HCC. Recent studies have shown that blocking blood vessels to a particular portion of the stomach (bariatric or left gastric artery embolization) can temporarily decrease levels of the appetite inducing hormone ghrelin, and result in weight loss.The purpose of this study is to determine if Left gastric artery embolization (LGAE) in patients with cirrhosis and HCC who are not transplant candidates due to morbid obesity, leads to clinically significant weight loss with eligibility for liver transplantation.

NCT ID: NCT00493610 Suspended - Hepatitis C Clinical Trials

Mucomyst for Hepatitis C

Start date: November 2006
Phase: N/A
Study type: Interventional

The study will examine the effects of treatment with N-acetylcysteine ( Mucomyst ) 1 gm twice a day for 30 dyas in 15 patients with hepatitis C. The primary outcome of interest wil be the changes in oxidant stress as measured by different oxidant stress markers level in sera. Secondary outcomes of interest will be changes in viral load of hep C and changes in liver function